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Pluripotent stem cells represent one promising source for cell replacement therapy in heart, but diﬀerentiating embryonic stem
cell-derived cardiomyocytes (ESC-CMs) are highly heterogeneous and show a variety of maturation states. In this study, we
employed an ESC clonal line that contains a cardiac-restricted ncx1 promoter-driven puromycin resistance cassette together with
a mass culture system to isolate ESC-CMs that display traits characteristic of very immature CMs. The cells display properties of
proliferation, CM-restricted markers, reduced mitochondrial mass, and hypoxia-resistance. Following transplantation into rodent
hearts,bioluminescenceimagingrevealedthatimmaturecells,butnotmorematureCMs,survivedforatleastonemonthfollowing
injection. These data and comparisons with more mature cells lead us to conclude that immature hypoxia resistant ESC-CMs can
be isolated in mass in vitro and, following injection into heart, form grafts that may mediate long-term recovery of global and
regional myocardial contractile function following infarction.
1.Introduction
The regenerative capacity of adult mammalian heart is
insuﬃcient to fully restore function following myocardial
injuryorheartfailure.Incasesofseverecardiacinsuﬃciency,
the treatment of choice is cardiac transplantation, but this
approach is hampered by both a severe shortage of donor
organs and the potential for organ rejection [1, 2]. Cell
replacement therapy represents one promising alternative,
but it is limited by the availability of transplantable human
cardiomyocytes (CMs). To overcome this limitation, car-
diovascular researchers have undertaken numerous stud-
ies over the past decade to identify cells in animal and
human systems with cardiomyogenic potential, including
cardiac derivatives isolated at various times of development
and noncardiac progenitors derived from bone-marrow,
fat, or skeletal muscle [3]. Subsequent preclinical studies
have demonstrated that a wide variety of cardiomyogenic
stem/progenitor cells can improve the cardiac function
after transplantation, but it remains largely unclear whether
improved cardiac function occurs through integration and
coupling of new CMs with endogenous cells (reviewed by
[4, 5]) or conversely through secondary events related to
angiogenesis, sparing of endogenous CMs, cell fusion, or
anti-inﬂammatory responses [6–10].2 Stem Cells International
W h i l en u m e r o u si n v e s t i g a t o r sh a v ed e s c r i b e dp u t a -
tive stem/progenitor cells with cardiomyogenic potential,
myocardial regeneration conﬁrmed through direct func-
tional coupling is limited to a few cell types [11, 12].
Among these, pluripotent stem cells (PSCs), including both
embryonic stem (ES) and induced pluripotent stem (iPS)
cells, represent the best viable cell source suitable for trans-
plantation therapy [13]. PSCs can be passaged indeﬁnitely
and can produce all body cells; consequently, these cells
are capable of treating a wide range of debilitating disease
states whose underlying pathology involves cell degenera-
tion, death, or acute injury. There are, however, signiﬁcant
challenges to be overcome before these approaches can be
applied in the clinic. Constraints to the use of human-
derived ESCs for cell therapy include ethical barriers and
potential immunogenicity of ESC-progeny [14, 15]. These
concerns may be overcome by iPS cells, which are generated
in vitro via transcription factor-mediated reprogramming
[16–18], but iPS cells also suﬀer from interline heterogeneity
and incomplete epigenetic remodeling [19–21]. Although
generation of suﬃcient numbers of cells for therapeutic
intervention is feasible, isolation of a desired cell type in
pure form, a systematic analysis of cell delivery systems, and
determination of which cell type may be necessary to correct
a speciﬁc pathology remain unanswered questions [14].
To deal with cell purity issues, several groups reported
isolation of ES cell-derived CMs (ESC-CMs) with cardiac-
restricted gene promoters (nkx2.5, cardiac α-mhc, mlc2v,
cardiac α-actin, ncx1)f r o mm o u s e ,h o w e v e r ,e a c hh a s
limitations. Some like nkx2.5 are not restricted to heart,
whereas others like α-mhc are only weakly expressed in
the primary myocardium before becoming restricted to
the atrial regions throughout the remainder of embryonic
and early fetal development [22, 23]. In adult rodents,
the mlc2v promoter is restricted to ventricle, but early in
development, its expression is present in anterior (atrial and
atrioventricular) portions of the heart tube, and at later
stages, in the caval myocardium [23, 24]. The cardiac α-
actin gene promoter is expressed both in cardiac and skeletal
muscle during embryogenesis [23]. Moreover, the distal
upstream region of the ncx1 promoter is cardiac-restricted
during embryonic and fetal development, but it does not
distinguish among chamber-speciﬁc types of heart cells
[25]. Functionally, ESC-CMs are most typical of embryonic
or fetal stages of development [23, 26], and no one has
successfully generated ESC-CMs in vitro with characteristics
of adult-derived ventricular CMs. Moreover, none of these
promoters have been employed in conjunction with stage-
speciﬁcanalysestodeterminewhichcelltypeandmaturation
state may be necessary to correct a speciﬁc pathology. The
goal of such a study would be to relate stage-speciﬁc CMs
with their suitability to regenerate damaged heart muscle.
In the current study, we have begun to test the hypothesis
that very immature but committed CMs may be suitable for
cardiac regenerative medicine. We have taken advantage of
murine ESCs containing a cardiac restricted ncx1 promoter-
drivenpuromycin-resistancegenethateliminatesnoncardiac
cells by antibiotic treatment and permits the isolation
of highly enriched and early-staged ESC-CMs [27, 28].
Developmentally, this promoter is active in proliferating
myocardium, and we previously showed that it could be
employed to isolate proliferative cells using a monolayer
culture and that late-stage nonproliferating cells could be
generated for therapeutic interventions. In this pilot study
designed to determine if early dividing CMs could be
isolated from a mass culture system in therapeutically
relevant quantities, we present our initial in vitro ﬁndings
and data following injection of these cells into the mouse
heart. These data indicate that early-staged ESC-CMs can
be isolated in therapeutic quantities, are hypoxic-resistant
and proliferative competent and potentially suitable to treat
myocardial infarctions.
2.MaterialsandMethods
2.1. Production of Highly Enriched ESC-CMs. Murine R1
ESCs (clone syNP4) that stably express a puromycin resistant
gene cassette under the cardiac-speciﬁc promoter of sodium
calcium exchanger (ncx1) were employed in this study.
Diﬀerentiation of ESCs to CMs was performed as previously
described, except where diﬀerences were noted in the text
[27, 28]. To track these cells following injection into mice
hearts, syNP4 cells were electroporated with an expression
cassette containing a mouse EF1α promoter-luciferase con-
struct and a hygromycin resistance cassette. Clonal lines
containing this construct with stable expression of luciferase
were isolated using standard protocols. Diﬀerentiation of
ESC-CMs and their purity and maturation were conﬁrmed
using RT-PCR with primers speciﬁc for α-SMA, cardiac
calsequestrin, and atrial natriuretic factor (ANF) [27, 28]
and by immunological techniques using antibodies against
α-smooth muscle actin (α-SMA, Biomeda, Foster City, CA),
sarcomeric α-actinin (Sigma, St. Louis, MO), cTnT (Milli-
pore, Billerica, MA), p21CIP (ab7960), p27KIP1 (ab7961), and
phospho-Ser10-Histone H3 (ab5176) (Abcam, Cambridge,
MA). CMs in the S phase of the cell cycle were identiﬁed by
5-Bromodeoxyuridine (BrdU) (Sigma) incorporation into
DNA as described previously [27].
2.2. Flow Cytometry. DNA content was determined from
ice cold 70% ethanol ﬁxed cells using a BD-Canto II after
staining with propidium iodide (PI, Sigma). Cell cycle
compartments were deconvoluted from single-parameter
DNAhistogramsof10,000to50,000cells,andDNAcellcycle
analysis was performed as previously described [27, 29]. Cell
viability based on mitochondrial membrane potentials and
mitochondrial content were determined using mitotracker
dyes according to the manufacturer’s instructions. Live
versus dead (apoptotic) cells were analyzed on a ﬂow
cytometer using 488nm excitation after labeling the cells
using a JC-1 mitochondrial membrane potential assay kit
(Invitrogen, Carlsbad, CA). In this assay, the cationic dye
JC-1 spontaneously forms complexes known as J-aggregates
that have intense red ﬂuorescence. In apoptotic or unhealthy
cells with a low membrane potential, JC-1 remains in the
monomeric form and shows only green ﬂuorescence. Mito-
chondria content was also estimated by staining cells with
MitoTracker Green FM (MTG), a mitochondrial-selectiveStem Cells International 3
green ﬂuorescent dye (Invitrogen, Carlsbad, CA). This probe
preferentially accumulates in mitochondria regardless of
mitochondrial membrane potential and is useful for deter-
mining mitochondrial mass. Cells were incubated in 200
micromolarconcentrationsoftheMTGprobefor30minutes
followed by ﬂow cytometry, according to the manufacturer’s
instructions.
2.3. Hypoxia and Nutrient Deprivation In Vitro. To induce
hypoxia, Day 10 and Day 18 ESC-CM cultures in
either glucose- and serum-free Dulbecco’s modiﬁed Eagle’s
medium (DMEM) or DMEM supplemented with 5.5mM
glucose and 10% heat-inactivated fetal bovine serum for
24 or 48 hours were transferred into a humidiﬁed hypoxic
incubator maintained at 37◦Cw i t h5 %C O 2,0 . 5 %O 2,a n d
the balance in N2 gas. Following incubation, culture media
was immediately collected to quantify total Lactate Dehydro-
genase (LDH, Sigma), an indicator of cell death and injury.
Cells were also harvested to measure viability via trypan blue
exclusion by two observers blind to experimental conditions.
2.4. In Vivo Studies. Surgical Procedures: all animal protocols
were approved by the local Institutional Animal Care and
Use Committee of the University of Pennsylvania. Surgical
procedures were performed on 8–10 athymic nude mice
(NCI) as we have described previously [30–32]. Brieﬂy,
animals were anesthetized using an induction dose of 3%
isoﬂurane. Mice were intubated, ventilated, and anesthesia
maintained with inhaled isoﬂurane (1% to 2%). An aseptic
left thoracotomy was performed and the pericardium was
opened. Mice then received a single mid-anterior intramy-
ocardial injection of 1-2 × 106 ESC-CMs in 50μLo fﬁ b r i n
glue. The developmental stage of the ESC-CMs is indicated
in the text.
In Vivo Bioluminescent Imaging (BLI): BLI was per-
formed on days 1, 3, 7, 14, 21, and 30 on IVIS Lumina
(CaliperLifeSciences,HopkintonMA)aswehaveshownpre-
viously[33, 34]. Mice were maintained under isoﬂurane (1%
mixed with oxygen) via a nose cone. Luciferin (250mg/kg)
was injected i.p. and continuous BLI was performed for
15min after injection. BLI signal was standardized for
exposure time and quantiﬁed in units of maximum photons
per second per square centimeter per steradian (p/s/cm2/sr).
Theareawiththegreatestsignalintensitywasusedforregion
of interest (ROI) analysis at each time point.
2.5.StatisticalAnalysis.Dataarepresentedasmean±standard
deviation. Student’s t-test was used to compare two groups,
and signiﬁcance was considered for P values of < 0.05.
3. Results
To test the ability of committed but proliferating ESC-CM
to form grafts in the heart, we had to demonstrate that
therapeutically relevant quantities of very immature cells
could be generated in vitro. For this, we took advantage of
an ESC line that was manipulated to express the puromycin
resistance (PacR) cassette under control of the cardiac-
restricted portion of the ncx1 promoter. Using the syNP4
clone and the classic hanging drop technique, we generated
CMs from >70–80% of the embryoid bodies (EBs). The
addition of ascorbic acid at day 2 of cultivation improves
this eﬃciency such that >90% of the EBs contain contracting
cells. As shown in Figure 1(a), following collagenase treat-
ment, the cells plate as a pseudo-monolayer characterized
by clusters of beating ESC-CMs found throughout the plate;
however, the total number of CMs is relatively low. When
selected by puromycin (2.5μg/mL), CMs can be isolated that
are ∼98% pure based on α-actinin or cTnT labeling in vitro
and by ﬂow cytometric analysis of cTnT labeled cells [27].
Here, we also show that cells isolated at early time points and
selected for at least 48 hours are transiently proliferative. As
previously described, cell cycle attributes can be assayed by
BrdU incorporation, Ser10 phosphorylation of histone H3,
and by increasing cell numbers on the plate (Figure 1(a)).
However, within 8–10 days of plating and selection (Day
7 + 8–10), the number of cells in G2/M decreases (P<
0.05), histone H3 phosphorylation at Ser10 is no longer
observed, and bi-nucleation increases (not shown). Here,
we also report that cell markers associated with contact
inhibition (proteins—p21CIP and p27KIP1) are upregulated
(Figure 1(b)) with time of diﬀerentiation, which together
with the cell cycle data, suggest that these cells rapidly
undergo a maturation process associated with the loss of
proliferativecapacity.Transcriptsfor α-smoothmuscleactin,
a marker of very early cardiac diﬀerentiation, are however
retained in these cells (Figure 1(b)).
When the syNP4 clone is cultured in a spinner ﬂask
systemfortheproduction of CMs,anumber of experimental
changes are required to achieve high yields of CMs [28]. The
system requires EB formation and suspension for 8-9 days
with media changes on a daily basis. At day 6, the addition
of BMP2 improves the yield of CMs, and selection with
puromycin begins at day 9. The partially selected EBs are
then collagenase dissociated and cultivated as a monolayer
culture. This method routinely produces ∼35 million ESC-
CM in a 16-17 day cycle after initial seeding of 25 million
ESC, and we have been able to reproduce these results
here (see Figure 1(c)). Consistent with our previous report,
CM enrichment at day 14 of diﬀerentiation estimated by
TnT staining was >85% when manually counted under
microscope but ranging from 75 to 92% by ﬂow cytometry
(Figure 1(d)). The cultures are however heterogeneous, and
the presence of α-smooth muscle actin protein is present in a
subset of these cells [28].
To isolate immature and potentially proliferative and
hypoxic resistant cells, we employed the same mass culture
system, except that diﬀerentiating syNP4 ESC-CMs were dis-
sociated at day 8 by collagenase treatment and immediately
treated with puromycin for 24 to 48 hours prior to analysis.
For all experiments, Day 9–11 cells were compared with Day
14–16 or Day 21 cells. At the earlier time point, the overall
yield of CMs is decreased signiﬁcantly, but when expanded
∼10 million or more cells can be routinely isolated. The
cellsplatedasapseudo-monolayer,andmostclustersshowed
asynchronous automaticity. Similar to the later staged cells
described earlier, the ESC-CMs were heterogeneous and
positive for α-SMA and α-actinin staining (Figure 2(a)). The4 Stem Cells International
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Figure 1: Characterization of syNP4 ES cell derived-CMs. (a) Traits of ESC-CM generated using the hanging drop technique. Following
diﬀerentiationandplating,puromycin-resistantcellsaggregateinclustersandshowspontaneouscontractions.Day8-9CMs(oneortwodays
after plating) readily incorporate BrdU (green) and dividing cells can be readily identiﬁed by the use of an antibody against a phosphorylated
form of histone H3. (b) As a function of diﬀerentiation time, syNP4 derived-CMs begin to express p21CIP and p27KIP1 markers of contact
inhibition and cell cycle checkpoint control, but the cells also continue to express transcripts to α-smooth muscle actin (α-SMA), a marker
of immature cardiomyocytes. (c) Using the mass culture system, plated puromycin-resistant syNP4-derived CMs cluster similarly to that
describedin1Aabove(seeinset).CellswereimmunostainedwithanantibodyagainstcardiacTnT(cTnT),demonstratingthattheseclusters
consist of CMs. (d) By ﬂow cytometry, the purity of the cells has been determined to range from 75 to 92% (n = 5), depending on the
cultivation and selection conditions. LC: loading control. Size markers = 50μm.
degree of maturation of ESC-CM as a function of diﬀerenti-
ation time is characterized by altered gene expression. More
speciﬁcally, the ratio of genes encoding ANF (early marker)
andcalsequestrin(latemarker)decreaseswithincreasedtime
of maturation (P<0.05). Calsequestrin is undetectable
by RT-PCR in very early Day 9-10 cells, prior to being
upregulated in Day 14–16 cells.
At selected time points, we measured DNA content on
propidium iodide- (PI, Sigma) stained nuclei from puro-
mycin selected ESC-CMs. Consistent with our previous
results with hanging drop derived ESC-CMs, the DNA
content of PI labeled cells showed an increase in the number
of G0/G1 cells and a decrease in G2/M phase cells between
days 9 and 14 of diﬀerentiation (Figure 2(b)). In contrast to
our previous report, no signiﬁcant change in the percentages
of S phase cells was observed during this time period. The
changesinG1versusG2/Mphasecellsis,however,consistent
with the isolation of a proliferating and consequentlyStem Cells International 5
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Figure 2: Characterization of immature syNP4 ES cell derived-CMs. (a) The purity and maturity of ESC-CMs at Day 11 were estimated
by costaining with anti-α-SMA (red) and anti-α-actinin (sarcomeric) (green) antibodies. All cells express α-SMA, while 90 ± 2% cells are
α-actinin positive. The right ﬁgure is a high magniﬁcation of the box in the left one. Arrows mark cells with α-SMA positive and α-actinin
negative staining. (b) The DNA content of puromycin-selected ESC-CMs generated by mass culture was determined following PI staining.
In these experiments (n = 3), the histogram indicates that Day 9 cells contain a higher percentage of G2/M phase cells than Day 14 cells. The
number of G0/G1 cells also tends to increase with time of diﬀerentiation (P>0.05). (c) Relative to controls, immature ESC-CMs incubated
with 1.5μM Jc1 had a strong increase in red ﬂuorescence, which based on membrane potentials is indicative of live cells. Moreover, lack of
change in membrane potential in either cell population indicates that the data shown from the MTG assay is directly comparable. (d) Typical
results from MTG-stained cells assessed by ﬂow cytometry. The green ﬂuorescence signal is directly proportional to the mitochondrial
content. As shown in the ﬁgure and table, the mitochondrial content increases with time of diﬀerentiation. (e) Cell viability of ESC-CMs
cultivated under hypoxic and nutrient deprivation conditions. Data are presented as a percentage of control values.
less mature cell population than those isolated at Days
14–16.
Mitochondria content/activity as a function of diﬀeren-
tiation time was estimated in the ESC-CMs by staining with
ﬂuorescent dyes and analysis by ﬂow cytometry (Figures 2(c)
and 2(d)). The cells were initially analyzed by ﬂow cytometer
to assess live versus apoptotic cells based on mitochondrial
membrane potentials. As shown in Figure 2(c),J C 1ﬂ u o -
rescence indicates that the vast majority (>90%) of Day
8 + 3 cells are alive (based on red versus green ﬂuorescence)
following selection. Mitochondria content as a function of
diﬀerentiation time was also estimated by staining ESC-CMs
with MTG, a mitochondrial-selective green ﬂuorescent dye.
ESC-CMs appear relatively rich in mitochondria, but impor-
tantly, the mitochondria content increases as a function of
diﬀerentiation time. The ﬂuorescence signals at Days 10, 18,
a n d2 5o fd i ﬀerentiation are 145±84, 206±44, and 225±57,
respectively (Figure 2(d)). This result shows that the content
of mitochondria in cells isolated at Day 10 is less than that
isolated at Day 18 or 25; and consequently, these cells should
be less sensitive to changes in oxygen content.
To test this possibility, we induced hypoxia and nutrient
depletion in these cells. Under hypoxic and glucose and
serum-deprived (double stress) conditions, early stage ESC-
CMs, which were isolated at Day 10, survived remarkably
better than those mature ESC-CMs isolated at Day 18
(Figure 2(e)). In these experiments, over 80% of Day 10
ESC-CMs were viable, which is on average 36% greater
than Day 18 cells at 48hrs. Consistently, under double stress
conditions, Day 18 ESC-CMs released much more total LDH
into the media than Day 10 cells. In fact, within 24 hours
the increase in LDH release from Day 18 cells was twofold
greater and at 48 hours threefold greater than that observed
from Day 10 cells.
Finally, to monitor survival of CMs grafted in the heart,
a subclone of syNP4 cells that stably express ﬁreﬂy luciferase
(Fluc) was established following selection with hygromycin.
Here, only one Fluc-expression sub-clone was employed for
in vivo analyses. In these experiments, 1-2 million ESC-
CMs (Day 8 + 3) selected by puromycin and expressing
Fluc were injected into the mid ventricular wall of a normal
(noninfarcted) heart in nude mice. Bioluminescent imaging
(BLI) was performed at days 1, 3, 7, 14, 21, and 30 post
transplantation, and the signal was quantiﬁed from an ROI
as described previously [35, 36]. As shown in (Figures 3(a)
and 3(b)), BLI signal from very immature ESC-CMs was
detectable for at least 30 days, whereas the signal from more
mature cells was lost within one week of injection. The signal
intensity observed in Figure 3(a) falls substantially during
the ﬁrst week, achieves a plateau from day 7 to 21, and
thendeclines further by 1month. Perhapsmore importantly,
Fluc signal was only detected in the thoracic region duringStem Cells International 7
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Figure 3:ImageanalysisofimmaturesyNP4-derived cardiomyocytes injected intoheart. (a,b)Representativelongitudinal bioluminescence
imaging (BLI) of athymic nude mice following intramyocardial transplantation of 2 × 106 syNP4-derived CMs stably expressing a ﬁreﬂy
luciferase reporter construct. The images shown in (a) involved CMs isolated at day 11 in culture, while those shown in (b) involved CMs
isolated at day 18. (c) Analysis of BLI data from two sets of ESC-CMs shows a robust cardiac signal on day1, which decreases substantially in
the ﬁrst week, achieves a plateau from days 7 to 21, and then declines at 1 month, whereas those cells, which are slightly more mature, have
minimal signals within 7 days of injection.8 Stem Cells International
the entire experiments, indicating that injected cells were
retained primarily at the site of injection. At least within the
detection limits of the method, the “wash out” cells either
did not take up residence elsewhere or did not survive in
noncardiac (e.g., liver) locations [37]. Finally, these mice
were examined for teratoma formation to ensure against
false Fluc signals due to tumor formation. In these animals,
no teratoma formation was observed in either experimental
group one month following injection (n = 2), conﬁrming
that early and proliferating CMs are not tumorgenic.
4. Discussion
During myocardial infarction, heart muscle is damaged by
ischemia due to a loss of blood ﬂow and a lack of oxygen.
Some if not most of the CMs in the aﬀected area may
survive brief and transient episodes of ischemia; however,
the longer the injury without treatment the more likely the
probability of signiﬁcant cell death. This occurs in part to
hypoxic stresses, mitochondrial dysfunction, pH changes,
and the accumulation of reactive oxygen species. If however
the ischemic episode is severe and is followed by reperfusion
astypically occursfollowing many coronaryocclusions, CMs
die in mass due to the opening of the membrane perme-
ability transition pore of the mitochondria. A spreading
wave of reactive oxygen species causes further damage. An
inﬂammatory response is mounted, and the process of left
ventricular remodeling begins shortly thereafter. This latter
process involves expansion of the infarcted area, ventricular
dilatation, extensive ﬁbrosis, and thinning of the ventricular
wall [38–41].
For cell-based therapies designed to treat heart failure to
become reality, problems associated with immunogenicity,
cell diﬀerentiation, and isolation, and delivery systems must
be overcome. While there is general agreement that ventric-
ular defects should be treated with ventricular cells, the stage
of cell maturation is also an area of active debate. This is
particularly true with regards to the ability of transplanted
cells to tolerate ischemic conditions. Cell replacement ther-
apy of a myocardial infarction, particularly after extensive
remodeling, is going to require the introduction of cells
into poorly vascularized and therefore hypoxic conditions.
Under these conditions, mature CMs are unlikely to survive;
however, immature CMs with innate hypoxic resistance
should survive to repopulate damaged tissue. Consistent
with this view, Reinecke et al. have shown that highly
diﬀerentiated adult CMs do not form viable grafts, which
makes adult hearts unsuitable as a source of donor cells
[42]. Moreover, in animal models, the vast majority of
neonatal CMs die within one week of grafting; however, a
modest improvement in survival is seen following grafting
into vascularized tissue [43]. Reinecke and coworkers also
documented that grafted fetal CMs survive and proliferate
in the impaired myocardium as well as in the normal
myocardium [42, 44]. Signiﬁcant eﬀort has therefore been
made to ﬁnd CMs that have the ability to improve left
ventricular function in damaged heart, and currently it
appears that fetal CMs are the best cell candidates for
myocardial repair.
For ethical reasons, fetal tissue sources cannot be used
to treat human heart failure; however, the derivation of
CMs from embryonic or adult stem cells with embryonic or
fetal-like characteristics represents one promising alternative
[14, 26, 45, 46]. These cells show a wide range of functional
attributes in part due to the state of maturation. Some
researchers have therefore advocated the use of more mature
stem cell-derived CMs that contain a developed contractile
apparatus and can integrate through gap junctions and
intercalated disks with host myocardium. When functionally
coupled, these cells should work to increase force gener-
ation and decrease the stresses on surviving CMs [47].
Alternatively, we and others have argued for the use of
progenitor cells or very immature but committed CMs that
have the capacity to integrate and mature in vivo. These
immature cells should ultimately form work-producing cells
that couple with endogenous cells. While there are merits
to both arguments, the appropriate cell type is likely to be
disorder (e.g., myocardial infarction, hypertrophic or dilated
cardiomyopathy) speciﬁc as well as location dependent; and
todate,noresearcheﬀortshavebeendesignedtoaddressthis
critical issue.
Here, we report the isolation of therapeutic quantities
of ESC-CMs that are functionally immature based on
automaticity, cell cycle analysis, hypoxia resistance, lower
mitochondrial mass, and the presence of markers typical
of immature embryonic or fetal heart cells. Because the
puromycinresistantcellsareallCMs,basedonpreviouselec-
trophysiological analyses and immunostaining, we conclude
that these cells are fully committed CMs, albeit nonchamber
speciﬁc [27]. Fijnvandraat et al. previously reported that
Day 7 to 13 ESC-CMs corresponded most closely to E8.75–
9 mouse heart cells based on a variety of chamber-speciﬁc
markers and electrophysiological properties [26]. The ESC-
CMs analyzed by patch clamp in that study all showed
automaticity, similar to what we observed here. While
contraction is observed in cells present in older cultures
(Day 14–21), it is not cell autonomous. Instead, synchronous
contractions are driven by the presence of pacemaker-like
cells [45], which has led investigators to conclude that later-
staged cells were most analogous to fetal or even neonatal
stages of development. Based on these published ﬁndings,
the presence of smooth muscle actin, time of diﬀerentiation,
and the dynamic proliferative capacity, we conclude that the
immature ESC-CMs described here correspond most closely
to cells present in mouse primary heart tube stage prior to
E8.75–9.
Moreover, we present the ﬁrst evidence to indicate that
these cells can in fact be introduced into myocardium, and
that the cells survive for at least one month in mouse
heart. Moreover, these cells survive preferentially to those
isolated at slightly later times of diﬀerentiation. We further
demonstrate that the puriﬁed ESC-CMs take up residence
in the myocardium without teratoma formation, at least
duringthetime-periodanalyzed,andthatFlucsignalscanbe
followed as a function of time to test therapeutic potentials.
Together with our recent publication utilizing more mature
cells [28], the development of this model system means that
we can begin addressing the possibility that committed andStem Cells International 9
proliferating CMs will be therapeutically superior to more
mature cells in the treatment of myocardial infarction.
5. Conclusions
In conclusion, we present data showing that the mass culture
system employed here can be adapted to generate immature
proliferatingCMstolerantofhypoxia.Withthedevelopment
of this system, ESC-CMs at deﬁned diﬀerentiation stages can
now be tested in vivo to determine their value for treatment
of myocardial infarctions. Techniques like cell surface cap-
turing technologies [48] will however be required to isolate
pure ventricular populations, but once accomplished, we
predict that the results will be analogous to those generated
with fetal, neonatal, and adult ventricular cells isolated
directly from heart. Early stage-speciﬁc CMs should lead to
increased cell survival and regeneration of damaged heart,
and once conﬁrmed in mouse, this approach could become
a powerful strategy for treating human cardiac disease states
and injuries.
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